New oral weight loss drug enters human testing
NCT ID NCT07166081
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial tests an experimental pill called BGM0504 in 80 non-diabetic adults who are overweight or obese. Participants receive either the drug or a placebo daily for several weeks. Researchers will check how the drug moves through the body, its safety, and whether it leads to weight loss.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BGM0504
- What this could lead to
- If successful, this could lead to a new oral medication for weight management in people who are overweight or obese.
- What could go wrong
- This is an early Phase 1 trial with only 80 participants, so safety and effectiveness are not yet proven. The drug may cause side effects or fail to show meaningful weight loss.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-DIABETIC OVERWEIGHT OR OBESE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Pharmaron CPC, Inc
RECRUITINGBaltimore, Maryland, 21201, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.